An independent committee have recommended GlaxoSmithKline pause a trial of its vaccine candidate against the respiratory syncytial virus (RSV), reports The Times.
The trial involved the creation of a vaccine to protect newborn children against RSV, which is a cause of pneumonia in toddlers and the elderly. It was designed to be given to pregnant women.
The trial was late-stage, with cause for holding it due to safety concerns. GlaxoSmithKline reported that they had agreed to pause enrollment and vaccination in the trial, as well as two other studies.
GSK added that a trial of its RSV vaccine for the over-60s would continue.
Analysts at Liberum said, “While the maternity trial pause was “disappointing”, the “big opportunity” for RSV vaccines was with older people, with potential sales of $2 billion.”
The shares traded down 12½p, or 0.8 per cent, at £15.67p.
For more stories from where you live, visit InYourArea.